Outcome MeasureDepression

RRS

Ruminative Response Scale

3 Papers in Blossom

Outcome Data Across Studies

Reported results for RRS across 1 study with quantitative data.

Outcome data across 8 study arm–timepoint observations
SD
Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
2022Secondary
Psilocybin + placebo(experimental)03059.7——
Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
2022Secondary
Psilocybin + placebo(experimental)423052.7—0.037
Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
2022Secondary
Psilocybin + escitalopram(active_comparator)02960.7——
Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
2022Secondary
Psilocybin + escitalopram(active_comparator)422960.4—0.037
Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
2022Secondary
Psilocybin + placebo(experimental)422149.0—0.037
Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
2022Secondary
Psilocybin + placebo(experimental)42961.3—0.037
Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
2022Secondary
Psilocybin + escitalopram(active_comparator)421454.7—0.037
Effects of psilocybin versus escitalopram on rumination and thought suppression in depression
2022Secondary
Psilocybin + escitalopram(active_comparator)421564.2—0.037

Papers Using RRS

Open Accessindividual

LSD microdosing in major depressive disorder: results from an open-label trial

This open-label Phase IIa trial (n=19, 15 male) found that an 8-week regimen of microdosed LSD (8μg initially, then 6-20μg twice weekly) for major depressive disorder was well-tolerated with no serious adverse events or cardiac valvulopathy, achieved 59.5% reduction in MADRS scores sustained for six months, and had only one withdrawal due to anxiety.

Published
Journal
Neuropharmacology
Authors
Daldegan-Bueno, D., Donegan, C. J., Sumner, R. L., Forsyth, A., Evans, W. J., Alshakhouri, M., Reynolds, L. M, Roop, P., Ponton, R., Smith, T., Hoeh, N. R., Allen, N., Sundram, F., Menkes, D. B., Muthukumaraswamy, S.
Open Accessindividual

Effects of psilocybin versus escitalopram on rumination and thought suppression in depression

In a randomised trial of 59 patients with major depressive disorder, psilocybin (COMP360) but not escitalopram produced significant reductions in rumination and thought suppression over 6 weeks; decreased thought suppression was specific to psilocybin responders while rumination fell in responders to both treatments. Reductions in both measures in the psilocybin arm correlated with ego dissolution and session-linked psychological insight, suggesting these processes may mediate its antidepressant effects.

Published
Journal
BJPsych Open
Authors
Barba, T., Buehler, S., Kettner, H., Radu, C., Cunha, G., Nutt, D. J., Erritzoe, D., Roseman, L., Carhart-Harris, R. L.
Open Accessindividual

Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression

In 19 patients with treatment-resistant depression, a single open‑label 25 mg dose of psilocybin reduced ventromedial prefrontal cortex–right amygdala functional connectivity during fearful and neutral (but not happy) face processing and increased amygdala connectivity with occipito‑parietal cortices. The decrease in vmPFC–amygdala coupling correlated with one‑week rumination scores, consistent with the hypothesis that psilocybin restores emotional responsiveness as a key therapeutic mechanism.

Published
Journal
Journal of Psychopharmacology
Authors
Mertens, L. J., Wall, M. B., Roseman, L., Demetriou, L., Nutt, D. J., Carhart-Harris, R. L.

Quick Facts

Full Name
Ruminative Response Scale
Domain
Depression
Papers Indexed
3
Score Range
22–88
Interpretation
Lower = better
Unit
points
All Measures